John Wrangle to Lung Neoplasms
This is a "connection" page, showing publications John Wrangle has written about Lung Neoplasms.
Connection Strength
1.825
-
Can We MIRror the Efficacy of Immune Checkpoints With miRNAs? J Thorac Oncol. 2020 11; 15(11):1703-1704.
Score: 0.396
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
Score: 0.332
-
Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. J Thorac Imaging. 2016 Jul; 31(4):238-42.
Score: 0.294
-
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget. 2013 Nov; 4(11):2067-79.
Score: 0.244
-
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. J Thorac Oncol. 2021 09; 16(9):1559-1569.
Score: 0.101
-
Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum. Clin Cancer Res. 2017 04 15; 23(8):1998-2005.
Score: 0.075
-
Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 2015 Jan 01; 6(1):56-70.
Score: 0.066
-
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63.
Score: 0.066
-
Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J Thorac Oncol. 2014 Jun; 9(6):752-9.
Score: 0.064
-
Extraction and processing of circulating DNA from large sample volumes using methylation on beads for the detection of rare epigenetic events. Clin Chim Acta. 2013 Oct 21; 425:169-75.
Score: 0.060
-
Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer. Ann Thorac Surg. 2012 Feb; 93(2):405-12.
Score: 0.054
-
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011 Dec; 1(7):598-607.
Score: 0.053
-
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017 06 22; 376(25):2415-2426.
Score: 0.020